Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report released on Thursday,Benzinga reports. D. Boral Capital currently has a $12.00 price target on the stock.

A number of other analysts also recently weighed in on the company. Maxim Group assumed coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target on the stock. Rodman & Renshaw assumed coverage on shares of Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price target on the stock. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 29th. Brookline Capital Management began coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Finally, EF Hutton Acquisition Co. I upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 22nd. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.50.

Quince Therapeutics Trading Up 0.5 %

NASDAQ:QNCX opened at $1.88 on Thursday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market cap of $82.72 million, a P/E ratio of -1.52 and a beta of 0.74. The stock’s 50 day simple moving average is $1.79 and its 200-day simple moving average is $1.10. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45.

Hedge Funds Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC raised its holdings in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 339,125 shares of the company’s stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.